Gilead Sciences, Inc. (gild)
GILD — Company Overview
Gilead Sciences, Inc. (GILD) is a large-cap company in the Healthcare sector, operating in Drug Manufacturers - General.
| Ticker | GILD |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Exchange | NMS |
| Market cap | $162.47B |
| Last price | $130.86 |
| Size category | Large Cap |
GILD — Business Description
Gilead Sciences, Inc. (GILD) operates in Drug Manufacturers - General within the broader Healthcare market. Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBiso…
Official website: https://www.gilead.com.
GILD — Investment Thesis
The investment thesis for Gilead Sciences, Inc. (GILD) rests on how Healthcare dynamics, profitability, and valuation interact at today's price.
- Revenue is expanding at roughly 10.2% year-over-year (public data).
- Dividend yield near 2.5% adds an income component to total return.
- Equity market capitalization is approximately $162.47B.
Analyst consensus, price targets & estimates is available in Vest Terminal for Professional and Enterprise subscribers.
GILD — Financial Health
Financial health for Gilead Sciences, Inc. (GILD) is summarized from publicly reported profitability, leverage, and cash-flow metrics.
Negative profit margin (-10.6%) signals near-term profitability pressure. Positive free cash flow of $12.17B supports balance-sheet flexibility. Debt-to-equity of 226.48 warrants monitoring in a higher-rate environment.
| Forward P/E | 13.30× |
| Price / Sales | 5.33× |
| Price / Book | 13.83× |
| Gross margin | 79.6% |
| Operating margin | 42.0% |
| Profit margin | -10.6% |
| Return on equity | -20.7% |
| Debt / Equity | 226.48 |
| Free cash flow | $12.17B |
GILD — Growth Outlook
Growth outlook for Gilead Sciences, Inc. (GILD) depends on demand trends in Drug Manufacturers - General and the company's ability to convert revenue into sustainable earnings.
- Revenue growth of 10.2% indicates strong top-line momentum.
- Price is 16.8% below the 52-week high.
- Shares trade 20.7% above the 52-week low — limited rebound so far.
GILD — Competitive Position
Gilead Sciences, Inc. (GILD) is evaluated against peers on scale, margin structure, and capital efficiency within Healthcare.
- Competes within Healthcare, specifically in Drug Manufacturers - General.
- Market capitalization of $162.47B places GILD among large-cap peers.
- Gross margin near 79.6% may reflect pricing power or favorable mix.
GILD — Strengths
Strengths for Gilead Sciences, Inc. (GILD) inferred from public financial metrics:
- Revenue growth of 10.2% year-over-year.
- Gross margin of 79.6% supports competitive unit economics.
- Positive free cash flow ($12.17B).
- Dividend yield of 2.5% for income-oriented holders.
- Large Cap scale ($162.47B) may provide distribution and funding advantages.
GILD — Weaknesses
Weaknesses and pressure points for Gilead Sciences, Inc. (GILD) based on available data:
- Thin profit margin (-10.6%).
- Elevated debt-to-equity (226.48).
GILD — Opportunities
- Sustained revenue growth (10.2%) could support multiple expansion if margins hold.
- Trading 20.7% above the 52-week low — potential recovery if fundamentals stabilize.
- Dividend yield of 2.5% appeals to total-return investors.
- Positive free cash flow enables reinvestment, debt reduction, or shareholder returns.
GILD — Risks
- Leverage (debt/equity 226.48) raises sensitivity to credit conditions.
- Thin margins leave less room for operational missteps.
GILD — Summary
Gilead Sciences, Inc. (GILD) is a large-cap Healthcare company focused on Drug Manufacturers - General, listed on NMS. Last price $130.86 with market cap $162.47B. Revenue grew 10.2% year-over-year per public data. Notable strengths include revenue growth of 10.2% year-over-year. Key watch items include thin profit margin (-10.6%). Detailed estimates, ownership, and news for Gilead Sciences, Inc. remain locked in Vest Terminal for subscribers.
Gilead Sciences, Inc. FAQ
What does Gilead Sciences, Inc. (GILD) do?
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor…
What is GILD's P/E ratio?
Gilead Sciences, Inc. has a trailing P/E of N/A× based on publicly available market data.
Does GILD pay a dividend?
Indicated dividend yield: 2.5%. Confirm ex-dates and payout history in Vest Terminal.
What sector is GILD in?
Gilead Sciences, Inc. is classified in Healthcare (Drug Manufacturers - General) on NMS.
What is GILD's market capitalization?
Approximate market cap: $162.47B.
What are the main risks for GILD?
Standard market, competitive, and execution risks apply; see the Risks section.
What are the strengths of GILD?
Potential positives include revenue growth of 10.2% year-over-year, gross margin of 79.6% supports competitive unit economics.
Where can I get analyst estimates for GILD?
Consensus estimates, price targets, and detailed analyst data for Gilead Sciences, Inc. are available to Professional subscribers in Vest Terminal — not on this public summary page.